A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS‐CoV‐2 vaccine

Murdych, Tomas M.

SARS-CoV-2 mRNA vaccine made by Pfizer and BioNTech was approved by the U.S. Food and Drug Administration for use under an Emergency Use Authorization for active immunization to prevent coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on December 11, 2020 (1). Intolerance reactions to the vaccine identified in the initial study were usually transient and mild to moderate (2). More serious and rare cases of anaphylaxis were reported following the emergency authorization with widespread vaccination efforts (3). Later, occurrence of immune thrombocytopenia and thromboembolic events in vaccine recipients (from different manufacturers) reached attention in general press (4) and in medical literature (5, 6). This is the first case published in the scientific literature of an individual with symptomatic, severe autoimmune hemolytic anemia diagnosed in the third week after receiving Pfizer-BioNTech Covid-19 vaccine, with recovery after corticosteroid therapy.